T Cell Specific Surface Glycoprotein CD28 Market Report 2026

T Cell Specific Surface Glycoprotein CD28 Market Overview

• T Cell Specific Surface Glycoprotein CD28 market size has reached to $1.62 billion in 2025 • Expected to grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.7% • Growth Driver: Growing Emphasis On Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Technologies • Market Trend: Breakthrough CD28 Approach Aims To Minimize Off-Target Toxicity In Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under T Cell Specific Surface Glycoprotein CD28 Market?

T cell-specific surface glycoprotein CD28 is a co-stimulatory receptor expressed on the surface of most T cells. It binds to B7 molecules (CD80/CD86) on antigen-presenting cells, delivering essential secondary signals for T cell activation, proliferation, and survival. Its primary purpose is to enhance immune responses by promoting cytokine production and preventing T cell anergy. The main types of T cell specific surface glycoprotein CD28 include FPT155, FR104, Lulizumab Pegol, and others. FPT155 is an investigational therapeutic protein that functions as an immune co-stimulatory fusion protein, targeting CD80 to activate T cells and enhance anti-tumor immune responses. These products utilize various technologies such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), western blotting, and immunohistochemistry, and are distributed through various channels including direct sales, distributors, e-commerce, retail pharmacies, and wholesalers. They are used in diverse applications such as immunology research, cancer research, autoimmune diseases, infectious diseases, and stem cell research, with key end users including hospitals, research laboratories, academic institutions, pharmaceutical companies, and diagnostic laboratories.

What Is The T Cell Specific Surface Glycoprotein CD28 Market Growth Forecast?

The t cell specific surface glycoprotein cd28 market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to development of lulizumab pegol and novel cd28 inhibitors, expansion of preclinical and clinical trials, integration of cd28-targeted therapies in autoimmune and cancer treatments, rising investment in biopharmaceutical research, advancement in immunomodulation and monoclonal antibody engineering. Major trends in the forecast period include increasing adoption of flow cytometry and elisa technologies, growth in immunology and cancer research applications, rising development of novel cd28 inhibitors and biobetters, expansion of stem cell and autoimmune disease research, integration of lulizumab pegol in preclinical and clinical studies.

Global T Cell Specific Surface Glycoprotein CD28 Market Segmentation

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types 2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry 3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers 4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research 5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories Subsegments: 1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships 2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations 3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering 4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Is The Driver Of The T Cell Specific Surface Glycoprotein CD28 Market?

The growing emphasis on personalized medicine is expected to propel the growth of the T cell-specific surface glycoprotein CD28 market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. T cell-specific surface glycoprotein CD28 supports personalized medicine by enabling targeted immune modulation, making therapies more precise and effective. It enhances treatment outcomes by promoting optimal T cell activation, improving patient-specific immune responses. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.

Key Players In The Global T Cell Specific Surface Glycoprotein CD28 Market

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Global T Cell Specific Surface Glycoprotein CD28 Market Trends and Insights

Major companies operating in the T cell-specific surface glycoprotein CD28 market are focusing on developing innovative products, such as the combination immunotherapies, to enhance T cell activation, anti-tumor efficacy, and patient treatment outcomes. Combination immunotherapies are treatments that combine multiple immune-based approaches to boost the body’s ability to fight disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, revealed preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody for advanced bladder cancer. It is engineered to selectively activate CD28 on T cells upon binding to Nectin-4-expressing tumor cells, enhancing T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, supporting further development as a potential therapy for patients with metastatic urothelial carcinoma.

What Are Latest Mergers And Acquisitions In The T Cell Specific Surface Glycoprotein CD28 Market?

In December 2024, Rondo Therapeutics Inc., a US-based biopharmaceutical company, partnered with Eli Lilly and Company to develop new CD28 bispecific antibodies for solid tumors. This partnership aims to enhance T cell co-stimulation and improve anti-tumor immune responses while minimizing immune-related toxicity, thereby advancing next-generation immuno-oncology therapies. Eli Lilly and Company is a US-based biopharmaceutical company developing CD28-targeted immuno-oncology therapies.

Regional Insights

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the T Cell Specific Surface Glycoprotein CD28 Market?

The T cell-specific surface glycoprotein CD28 market consists of revenues earned by entities by providing services such as drug discovery, antibody development, cell signaling assays, immuno-oncology research, diagnostic testing, and clinical trial support targeting CD28 pathways. The market value includes the value of related goods sold by the service provider or included within the service offering. The T cell-specific surface glycoprotein CD28 market also includes sales of CD28 fusion proteins, CD28 ligands, flow cytometry reagents, and diagnostic assays and kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the T Cell Specific Surface Glycoprotein CD28 Market Report 2026?

The t cell specific surface glycoprotein cd28 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the t cell specific surface glycoprotein cd28 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.